戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 er pretreatment with a sequential regimen of cyproterone acetate (50 mg/kg/day for 21 days) and testo
2                                              Cyproterone acetate (CPA) is a steroidal antiandrogen us
3 tetrachloride (CT), thioacetamide (THA), and cyproterone acetate (CPA).
4 This event was blocked by the anti-androgens cyproterone acetate and hydroxyflutamide.
5                 Increasing concentrations of cyproterone acetate and mifepristone resulted in more co
6                         Molecular docking of cyproterone acetate and RU486 into the homology model fo
7 tar-Unilever rats by a sequential regimen of cyproterone acetate and testosterone propionate, followe
8                               The antagonist cyproterone acetate behaved as a full antagonist of D11F
9 hibited by the addition of the anti-androgen Cyproterone Acetate demonstrating that the effects of FG
10  cells, RU486 revealed a higher potency than cyproterone acetate to prevent responses to dexamethason
11     The agonist activity of the antiandrogen cyproterone acetate was abolished in ebp1 transfectants.
12                         The steroid compound cyproterone acetate was identified in a high-throughput
13 ties of weak androgens and an AR antagonist (cyproterone acetate) are still dependent on the AR NH(2)
14                             AR activation by cyproterone acetate, a partial agonist that did not supp
15 s seen only with R1881, dihydrotestosterone, cyproterone acetate, and hydroxyflutamide.
16 s, hydroxyflutamide, bicalutamide (casodex), cyproterone acetate, and RU58841, and other compounds su
17 ol and medroxyprogesterone) and antagonists (cyproterone acetate, hydroxyflutamide and bicalutamide).
18 ynthetic potent progestigens, norethynodrel, cyproterone acetate, norethindrone, and megestrol acetat
19 ta-catenin to the AR DBD in vitro and to the cyproterone acetate-liganded AR in vivo.
20 th DHT in combination with the anti-androgen cyproterone acetate.
21 orticoid spironolactone and the antiandrogen cyproterone acetate.
22                    The binding affinities of cyproterone and RU486 for the GR and progesterone recept
23               However, in contrast to RU486, cyproterone lacks a bulky side chain at position C11 bet
24                                              Cyproterone may therefore inhibit transactivation of the
25                                              Cyproterone (Schering AG) is clinically used as an antia
26            Despite its progestin properties, cyproterone shares a similar pharmacological profile wit

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。